Our Company

Recognizing the plethora of potential first- and best-in-class candidates out of China and other geographic areas such as Europe, South Korea and Japan—and the risk that these might never make it to market due to development challenges in the areas in which they were discovered—we have made it our mission to ensure these innovations get into the hands of patients and physicians across the globe.

This is R&D
Done Differently

At Arrivent

we understand that human cancer is a complex set of diseases which requires diverse therapeutic approaches to provide the most benefit to patients. For that reason, we are therapeutic-class agnostic in our ability to identify and rapidly develop innovative medicines for cancer patients regardless of where the drug was initially discovered. We leverage our scientific knowledge and broad experience in oncology drug development to identify first-in-class and/or best-in-class medicines with strong development potential, and work seamlessly with scientific founders and their companies to bring these drugs to patients globally as quickly as possible.

Our lead clinical asset firmonertinib is an example of how we are building our pipeline based on a strong understanding of cancer biology and unmet medical need, and we are applying these same skills to other medicines and research collaborations as well.